	US 11,952,414 B2
	Peptide used for immunotherapeutics
Hyo Joon Kim, Gyeonggi-Do (KR)
Assigned to 3H BIO. CO., LTD., Gyeonggi-do (KR)
Filed by 3H BIO. CO., LTD., Gyeonggi-do (KR)
Filed on Aug. 30, 2022, as Appl. No. 17/823,180.
Application 17/823,180 is a continuation of application No. 17/639,547, previously published as PCT/KR2021/009453, filed on Jul. 21, 2021.
Claims priority of application No. 10-2020-0091031 (KR), filed on Jul. 22, 2020; application No. 10-2020-0091032 (KR), filed on Jul. 22, 2020; and application No. 10-2020-0091033 (KR), filed on Jul. 22, 2020.
Prior Publication US 2023/0087676 A1, Mar. 23, 2023
Int. Cl. C07K 14/775 (2006.01); A61K 38/16 (2006.01); A61P 3/04 (2006.01); C07K 14/435 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/775 (2013.01) [A61K 38/16 (2013.01); A61P 3/04 (2018.01); C07K 14/435 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)]

3 Claims

1. A peptide comprising an amino acid sequence, wherein the amino acid sequence comprises RNVPPIFNDVYWIAFZaK(Cha)VAAWTLKAACR (SEQ ID NO: 161), wherein the “a” denotes D-form alanine, the “(Cha)” denotes L-cyclohexylanine, and the “Z” denotes 6-aminohexanoic acid.